A new adjuvant treatment with polyadenylic-polyuridylic acid in operable breast cancer.

F. Lacour, J. Lacour, A. Spira, M. Michelson, G. Delage, J. Y. Petit, J. Viguier

Research output: Contribution to journalArticlepeer-review

Abstract

Adjuvant treatment with polyadenylic-polyuridylic acid poly A-poly U was tested in 300 patients with operable breast cancer who had all received the same locoregional treatment. They were randomized into two groups; 155 patients receiving 30 mg poly A-poly U i.v. once a week for 6 weeks and 145 controls. Overall survival was significantly improved in the poly A-Poly U group (P less than 0.05). The most striking difference (less than 0.03) was observed in the group of positive node patients, who had a 5-year relapse-free actuarial survival rate of 71% versus 47% in the controls.

Original languageEnglish
Pages (from-to)200-206
Number of pages7
JournalRecent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer
Volume80
Publication statusPublished - 1982

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'A new adjuvant treatment with polyadenylic-polyuridylic acid in operable breast cancer.'. Together they form a unique fingerprint.

Cite this